Overview

Piclidenoson for Treatment of COVID-19

Status:
Recruiting

Trial end date:
2022-07-06

Target enrollment:

Participant gender:

Summary

Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28 days.

Phase:

Phase 2

Details

Lead Sponsor:

Can-Fite BioPharma

Collaborator:

Rabin Medical Center